Veneris, Jennifer
Dana-Farber Cancer Institute
2 papers on CoChatORCID 0000-0002-0537-8534
Most cited papers
- Verified
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Corcoran, R. B., Do, K. T., Kim, J. E., Cleary, J. M., Parikh, A. R., Yeku, O. O., Xiong, N., Weekes, C. D., Veneris, J., Ahronian, L. G., et al. (2024) · Clinical Cancer Research
Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling
Cited by 46
- Verified
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
Corcoran, R. B., Do, K. T., Cleary, J. M., Parikh, A. R., Yeku, O. O., Weekes, C. D., Veneris, J., Ahronian, L. G., Mauri, G., Van Seventer, E. E., et al. (2019) · Annals of Oncology
Melanoma and MAPK PathwaysCell death mechanisms and regulation
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free